摘要:
A composition for the treatment of acne includes hydrolyzed psoralea corylifolia, containing a component bakuchiol, is solubilized in a water-based solution. The composition is for topical application to the skin. In various implementations, the composition is a water-based acne gel or a water-based cleanser. In a specific implementation, a composition includes Bakutrol(TM), which includes bakuchiol, and bisabolol. The composition can include a polysorbate surfactant. In implementations, these ingredients are combined with other active ingredients, including for example, salicylic acid, benzoyl peroxide, tretinoin, retinol, tazarotene, or an antibiotic, or a combination of these. A process of preparation of the composition allows for the stabilization of Bakutrol in solution.
摘要:
A composition for the treatment of acne includes hydrolyzed Psoralea Corylifolia, containing a component bakuchiol, is solubilized in a water-based solution. The composition is for topical application to the skin. In a specific implementation, the composition is a water-based acne gel. In a specific implementation, a composition includes Bakutrol™, which includes bakuchiol, and bisabolol. The composition can include a polysorbate surfactant. In implementations, these ingredients are combined with other active ingredients, including for example, salicylic acid. A process of preparation of the composition allows for the stabilization of Bakutrol in solution.
摘要:
A composition for inhibiting ketohexokinase, for example, ketohexokinase-C (KHK-C) activity, may include a plant extract exhibiting at least IC50 (i.e., 50% KHK-C inhibition at a concentration in the range of from about 0.1 μg/mL to about 1000 μg/mL. The composition may be in a form suitable for oral ingestion. A method for inhibiting KHK-C activity in a subject may include administering a plant extract that exhibits at least 50% KHK-C inhibition at a concentration from about 0.1 μg/mL to about 1000 μg/mL. The administering may be done to treat or prevent at least one of sugar addiction, obesity, or metabolic syndrome. The administering may be done to provide a diminished craving in the subject from at least one member selected from the group consisting of craving of sugar, fructose, fructose-containing sugars, carbohydrates, and combinations thereof. The subject may be pre-diabetic, diabetic and or insulin resistant.
摘要:
A composition for the treatment of acne includes hydrolyzed Psoralea Corylifolia, containing a component bakuchiol, is solubilized in a water-based solution. The composition is for topical application to the skin. In a specific implementation, the composition is a water-based acne gel. In a specific implementation, a composition includes Bakutrol(TM), which includes bakuchiol, and bisabolol. The composition can include a polysorbate surfactant. In implementations, these ingredients are combined with other active ingredients, including for example, salicylic acid. A process of preparation of the composition allows for the stabilization of Bakutrol in solution.
摘要:
A skin treatment composition or cosmetic product comprising a) two or more active components, namely, at least one dermatological acid and at least one meroterpene and b) a dermatologically acceptable carrier.
摘要:
Die Erfindung betrifft eine Kräutermischung basierend auf TCM (Traditioneller Chinesischer Medizin), zur Verstärkung der Nieren- und Blasenfunktion gegen Blasenschwäche, sowie zur Leistungssteigerung des menschlichen Organismus. Die Erfindung unterstützt den Schliess- und Ringmuskel zu stärken für die verbesserte Kontolle beim Harngang. Die Erfindung umfasst 6 Zutaten. Diese wird zu Granulat verarbeitet oder als Extrakt gewonnen und oral eingenommen. Astragalus memeranaceus (Fisch.) 10-20%, Cynanchum otophyllum Schneid. 10-20%, Crataegus pinnatifida Bunge 10-20%, Psoralea corylifolia Linn., 20-30%, Rosa laevigata Michx. 20-30%, Cornus officinalis Sieb. et Zucc. 20-30%. Diese Erfindung bezieht sich auf die Zusammensetzung und Extrakt des gleichen.
摘要:
A skin treatment composition or cosmetic product comprising a) two or more active components, namely, at least one dermatological acid and at least one meroterpene and b) a dermatologically acceptable carrier.